Table 1 Patient’s clinical features at first visit
From: Dose-dependence of protection from systemic reactions to venom immunotherapy by omalizumab
Age at first visit in our clinic | 47 years old |
|---|---|
Sex | Female |
Concomitant allergies | None |
Concomitant diseases | None |
Previous systemic reactions of grade IV Muller | Yes |
Number of previous attempts of VIT with HB venom withdrawn for repeated systemic reactions during build-up phase | 3 |
Skin test | Prick test HB venom: 20 mm (hystamine: 10 mm) |
Total IgE | 51 kU/l |
s-IgE HB | 20.3 U/ml |
s-IgE Api m 1 | 7.93 U/ml |
s-IgE Api m 10* | 0.00 U/ml |
s-IgE CCD | 0.00 U/ml |
Basal tryptase | 2.4 ng/ml |
Mastocytosis in bone marrow (biopsy performed)** | Absent |
KIT mutation** | Absent |